BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10202883)

  • 1. Reference values for the midluteal plasma progesterone concentration: evidence from human menopausal gonadotropin-stimulated pregnancy cycles.
    Sallam HN; Sallam A; Ezzeldin F; Agamia AF; Abou-Ali A
    Fertil Steril; 1999 Apr; 71(4):711-4. PubMed ID: 10202883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal requirements for a successful outcome in anovulatory patients treated with human menopausal gonadotropins.
    Sallam HN; Sallam AN; Ezzeldin FE; Agamia AF; Abou-Ali AH
    Int J Fertil Womens Med; 2000; 45(4):285-91. PubMed ID: 10997485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteal phase support with hCG does not improve fecundity rate in human menopausal gonadotropin-stimulated cycles.
    Keenan JA; Moghissi KS
    Obstet Gynecol; 1992 Jun; 79(6):983-7. PubMed ID: 1579327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early detection of multiple gestations following hMG-hCG therapy by ultrasonography and midluteal phase progesterone determinations.
    Tanaka T; Sakuragi N; Fujimoto S; Ichinoe K; Mizoe J
    Int J Fertil; 1983; 28(3):184-7. PubMed ID: 6140241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimum values for midluteal plasma progesterone and estradiol concentrations in patients who achieved pregnancy with timed intercourse or intrauterine insemination without a human menopausal gonadotropin.
    Takaya Y; Matsubayashi H; Kitaya K; Nishiyama R; Yamaguchi K; Takeuchi T; Ishikawa T
    BMC Res Notes; 2018 Jan; 11(1):61. PubMed ID: 29357944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteal phase hyperprolactinemia during ovulation induction with human menopausal gonadotropins: incidence, recurrence, and effect on pregnancy rates.
    Tippet PD; Simon JA; Rifka SM; Falk RJ
    Obstet Gynecol; 1989 Apr; 73(4):613-6. PubMed ID: 2494621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Peak follicular estradiol (E2) levels and midluteal progesterone/E2 ratios in ongoing pregnancies and nonconception cycles after ovulation induced with gonadotropins].
    Ellenbogen A; David H; Libal Y; Ballas S
    Harefuah; 1995 Dec; 129(11):455-6, 536. PubMed ID: 8846950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shortened luteal phase after ovulation induction with human menopausal gonadotropin and human chorionic gonadotropin.
    Olson JL; Rebar RW; Schreiber JR; Vaitukaitis JL
    Fertil Steril; 1983 Mar; 39(3):284-91. PubMed ID: 6402386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction.
    Blumenfeld Z; Lang N; Amit A; Kahana L; Yoffe N
    Fertil Steril; 1994 Sep; 62(3):456-60. PubMed ID: 8062938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteal dysfunction in ovulation induction: the role of repetitive human chorionic gonadotropin supplementation during the luteal phase.
    Blumenfeld Z; Nahhas F
    Fertil Steril; 1988 Sep; 50(3):403-7. PubMed ID: 3137096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of progesterone/estradiol ratio on luteal function for achieving pregnancy in gonadotropin therapy.
    Kamada S; Kubota T; Aso T
    Horm Res; 1992; 37 Suppl 1():59-63. PubMed ID: 1427631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of luteal phase support protocol on cycle outcome and luteal phase hormone profile in long agonist protocol intracytoplasmic sperm injection cycles: a randomized clinical trial.
    Ghanem ME; Sadek EE; Elboghdady LA; Helal AS; Gamal A; Eldiasty A; Bakre NI; Houssen M
    Fertil Steril; 2009 Aug; 92(2):486-93. PubMed ID: 19464001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinizing response to human chorionic gonadotropin does not predict outcome in gonadotropin releasing hormone agonist-suppressed/human menopausal gonadotropin-stimulated in vitro fertilization (IVF) cycles.
    Penzias AS; Shamma FN; Gutmann JN; Seifer DB; DeCherney AH; Lavy G
    J Assist Reprod Genet; 1992 Jun; 9(3):244-7. PubMed ID: 1525454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of ovulation with pulsatile subcutaneous administration of human menopausal gonadotropin in anovulatory infertile women.
    Nakamura Y; Yoshimura Y; Tanabe K; Iizuka R
    Fertil Steril; 1986 Jul; 46(1):46-54. PubMed ID: 3087790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of elevated serum progesterone during ovulation induction in in vitro fertilization-embryo transfer.
    Huang JC; Jackson KV; Hornstein MD; Ginsburg ES
    J Assist Reprod Genet; 1996 Sep; 13(8):617-24. PubMed ID: 8897120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of luteal support with progesterone in gonadotropin-induced cycles.
    Hamilton CJ; Jaroudi KA; Sieck UV
    Fertil Steril; 1993 Nov; 60(5):786-90. PubMed ID: 8224262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles.
    Kuang Y; Hong Q; Chen Q; Lyu Q; Ai A; Fu Y; Shoham Z
    Fertil Steril; 2014 Jan; 101(1):105-11. PubMed ID: 24161646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone and ultrasound parameters in ovarian stimulation cycles for direct intraperitoneal insemination.
    Karlström PO; Bakos O; Bergh T; Lundkvist O
    Hum Reprod; 1992 Jul; 7(6):813-20. PubMed ID: 1500480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midluteal Progesterone: A Marker of Treatment Outcomes in Couples With Unexplained Infertility.
    Hansen KR; Eisenberg E; Baker V; Hill MJ; Chen S; Talken S; Diamond MP; Legro RS; Coutifaris C; Alvero R; Robinson RD; Casson P; Christman GM; Santoro N; Zhang H; Wild RA;
    J Clin Endocrinol Metab; 2018 Jul; 103(7):2743-2751. PubMed ID: 29767754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.